Prior studies with this ISIM treatment in the primary treatment setting demonstrated that it increased frequencies of activated, effector CD4+ and CD8+ T cells in AT-3 murine tumors (114) and decreased PMN-MSDCs in AT-3 and 4T1 BC murine tumors (115). The gene discussed is CD8A; the disease is breast cancer.